Risk factor
Good trading liquidity
Profitability factor
Greatly overvalued vs peers
About
Sichuan Huiyu Pharmaceutical Co., Ltd. researches, develops, produces, and sells anti-tumor injection in China and internationally. It offers injection drug products, such as pemetrexed disodium, methrotrexate, docetaxel, azacitidine, oxaliplatin, cyclophosphamide, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, decitabine, palonosetron hydrochloride, plerixafor, levetiracetam concentrated solution, amifostine, levofolate calcium, thiotepa, fulvestrant, and milrinone drugs. The company also offers moroxydine sodium chloride, fluorouracil, sodium thiosulfate, acetylcysteine, nimodipine, nimodipine, dihydroxypropyltheophylline, cisatracurium besylate, cladribine, sodium carbosulfan, octreotide acetate, mesobamo, doxorubicin, leucovorin calcium, famotidine, etoposide, polymyxin B sulfate, melphalan hydrochloride, teicoplanin, epirubicin hydrochloride, gemcitabine hydrochloride, cytarabine, voriconazole, roxatidine acetate hydrochloride, and bortezomib drugs. Sichuan Huiyu Pharmaceutical Co., Ltd. was incorporated in 2010 and is headquartered in Neijiang, China.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA